Advertisement

Breast Cancer Research and Treatment

, Volume 167, Issue 3, pp 615–633 | Cite as

Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review

  • Leah K. Lambert
  • Lynda G. Balneaves
  • A. Fuchsia Howard
  • Carolyn C. Gotay
Review

Abstract

Background

Adjuvant endocrine therapy (AET) significantly reduces recurrence and mortality in women with breast cancer (BrCa). Despite the efficacy of AET in improving BrCa outcomes, up to 50% of women do not adhere to prescribed AET regimens. While numerous demographic and clinical predictors influence adherence and persistence, few studies have identified the patient-reported factors that influence AET adherence and persistence.

Purpose

The aim was to examine the patient-reported personal, social, and structural factors influencing BrCa survivors’ adherence and persistence with AET.

Methods

An integrative review was undertaken wherein PubMed, Medline, CINAHL, Embase, and PsycINFO databases were searched using keyword descriptors and database subject headings. Inclusion criteria included quantitative or qualitative peer-reviewed studies written in English that assessed AET adherence and/or persistence through objective measurement or self-report and included patient-reported factors found to influence adherence and/or persistence. The data extracted from eligible studies were entered into a matrix, and systematically compared and iteratively analyzed using relational autonomy as an organizing theoretical framework.

Results

A total of 43 manuscripts (9 qualitative and 34 quantitative) were reviewed. Several personal, social, and structural factors were identified that influenced AET adherence and persistence, including side effects, necessity beliefs, self-efficacy, the patient–healthcare provider relationship, social support, and continuity of follow-up care.

Conclusions

An increasing number of studies have focused on identifying the patient-reported factors that influence AET adherence and persistence. This review highlights important personal, social, and structural factors that act as facilitators and barriers in adhering to and persisting with long-term AET. Acknowledging and addressing these factors is key to providing women with the care needed to improve suboptimal adherence and persistence.

Keywords

Breast cancer Adjuvant endocrine therapy Medication adherence Medication persistence Integrative review Cancer survivorship Patient-reported outcomes 

Abbreviations

AET

Adjuvant endocrine therapy

AI

Aromatase inhibitor

BrCa

Breast cancer

HCP

Healthcare provider

QOL

Quality of life

Notes

Acknowledgements

LKL was supported by a University of British Columbia Four-Year Fellowship and a CIHR Psychosocial Oncology Research Training (PORT) Fellowship.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    International Agency for Research on Cancer (2012) GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
  2. 2.
    Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792.  https://doi.org/10.1097/01.ogx.0000201966.23445.91 CrossRefPubMedGoogle Scholar
  3. 3.
    Burstein HJ, Prestrud AA, Seidenfeld J et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784–3796.  https://doi.org/10.1200/JCO.2009.26.3756 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Hershman D, Shao T, Kushi L et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529–537.  https://doi.org/10.1007/s10549-010-1132-4 CrossRefPubMedGoogle Scholar
  5. 5.
    Burstein HJ, Temin S, Anderson H et al (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 32:2255–2269.  https://doi.org/10.1200/JCO.2013.54.2258 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805–816.  https://doi.org/10.1016/S0140-6736(12)61963-1 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hershman DL, Kushi LH, Shao T et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28:4120–4128.  https://doi.org/10.1200/JCO.2009.25.9655 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Owusu C, Buist DSM, Field TS et al (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26:549–555.  https://doi.org/10.1200/JCO.2006.10.1022 CrossRefPubMedGoogle Scholar
  9. 9.
    van Herk-Sukel MPP, van de Poll-Franse LV, Voogd AC et al (2010) Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat 122:843–851.  https://doi.org/10.1007/s10549-009-0724-3 CrossRefPubMedGoogle Scholar
  10. 10.
    Murphy CC, Bartholomew LK, Carpentier MY et al (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134:459–478.  https://doi.org/10.1007/s10549-012-2114-5 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Gotay C, Dunn J (2011) Adherence to long-term adjuvant hormonal therapy for breast cancer. Expert Rev Pharmacoecon Outcomes Res 11:709–715.  https://doi.org/10.1586/erp.11.80 CrossRefPubMedGoogle Scholar
  12. 12.
    Chlebowski RT, Geller ML (2007) Adherence to endocrine therapy for breast cancer. Oncology 71:1–9.  https://doi.org/10.1159/000100444 CrossRefGoogle Scholar
  13. 13.
    Banning M (2012) Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review. Eur J Cancer Care (Engl) 21:10–19.  https://doi.org/10.1111/j.1365-2354.2011.01295.x CrossRefGoogle Scholar
  14. 14.
    Whittemore R, Knafl K (2005) The integrative review: updated methodology. J Adv Nurs 52:546–553.  https://doi.org/10.1111/j.1365-2648.2005.03621.x CrossRefPubMedGoogle Scholar
  15. 15.
    Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467.  https://doi.org/10.1016/S0140-6736(97)11423-4 CrossRefGoogle Scholar
  16. 16.
    Van Liew JR, Christensen AJ, de Moor JS (2014) Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research. J Cancer Surviv 8:521–531.  https://doi.org/10.1007/s11764-014-0374-2 CrossRefPubMedGoogle Scholar
  17. 17.
    Cahir C, Guinan E, Dombrowski SU et al (2015) Identifying the determinants of adjuvant hormonal therapy medication taking behaviour in women with stages I–III breast cancer: a systematic review and meta-analysis. Patient Educ Couns 98:1524–1539.  https://doi.org/10.1016/j.pec.2015.05.013 CrossRefGoogle Scholar
  18. 18.
    Wuensch P, Hahne A, Haidinger R et al (2015) Discontinuation and non-adherence to endocrine therapy in breast cancer patients: is lack of communication the decisive factor? J Cancer Res Clin Oncol 141:55–60.  https://doi.org/10.1007/s00432-014-1779-z CrossRefPubMedGoogle Scholar
  19. 19.
    World Health Organization (2003) Adherence to long-term therapies: evidence for action. WHO, GenevaGoogle Scholar
  20. 20.
    U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 4:79.  https://doi.org/10.1186/1477-7525-4-79 CrossRefGoogle Scholar
  21. 21.
    Howell D, Fitch M, Bakker D et al (2013) Core domains for a person-focused outcome measurement system in cancer (PROMS-cancer core) for routine care: a scoping review and Canadian delphi consensus. Value Health 16:76–87.  https://doi.org/10.1016/j.jval.2012.10.017 CrossRefPubMedGoogle Scholar
  22. 22.
    Howell D, Molloy S, Wilkinson K et al (2015) Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol 26:1846–1858.  https://doi.org/10.1093/annonc/mdv181 CrossRefPubMedGoogle Scholar
  23. 23.
    Whittemore R (2005) Combining evidence in nursing research: methods and implications. Nurs Res 54:56–62.  https://doi.org/10.1097/00006199-200501000-00008 CrossRefPubMedGoogle Scholar
  24. 24.
    Burns N (1989) Standards for qualitative research. Nurs Sci Q 2:44–52.  https://doi.org/10.1177/089431848900200112 CrossRefPubMedGoogle Scholar
  25. 25.
    Sherwin S (1998) A relational approach to autonomy in health care. In: Sherwin S (ed) Politics of women’s health. Exploring agency and autonomy. Temple University Press, Philadelphia, pp 19–47Google Scholar
  26. 26.
    Friese CR, Pini TM, Li Y et al (2013) Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat 138:931–939.  https://doi.org/10.1007/s10549-013-2499-9 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Bradley CJ, Dahman B, Jagsi R et al (2015) Prescription drug coverage: implications for hormonal therapy adherence in women diagnosed with breast cancer. Breast Cancer Res Treat 154:417–422.  https://doi.org/10.1007/s10549-015-3630-x CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Fink AK, Gurwitz J, Rakowski W et al (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22:3309–3315.  https://doi.org/10.1200/JCO.2004.11.064 CrossRefPubMedGoogle Scholar
  29. 29.
    Lash TL, Fox MP, Westrup JL et al (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99:215–220.  https://doi.org/10.1007/s10549-006-9193-0 CrossRefPubMedGoogle Scholar
  30. 30.
    Cluze C, Rey D, Huiart L et al (2012) Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol 23:882–890.  https://doi.org/10.1093/annonc/mdr330 CrossRefPubMedGoogle Scholar
  31. 31.
    Huiart L, Bouhnik A-D, Rey D et al (2012) Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed? Eur J Cancer 48:1939–1946.  https://doi.org/10.1016/j.ejca.2012.03.004 CrossRefPubMedGoogle Scholar
  32. 32.
    Wouters H, Stiggelbout AM, Bouvy ML et al (2014) Endocrine therapy for breast cancer: assessing an array of women’s treatment experiences and perceptions, their perceived self-efficacy and nonadherence. Clin Breast Cancer 14(460–467):e2.  https://doi.org/10.1016/j.clbc.2014.04.005 Google Scholar
  33. 33.
    Wouters H, Maatman GA, Van Dijk L et al (2013) Trade-off preferences regarding adjuvant endocrine therapy among women with estrogen receptor-positive breast cancer. Ann Oncol 24:2324–2329.  https://doi.org/10.1093/annonc/mdt195 CrossRefPubMedGoogle Scholar
  34. 34.
    Stanton AL, Petrie KJ, Partridge AH (2014) Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry. Breast Cancer Res Treat 145:525–534.  https://doi.org/10.1007/s10549-014-2961-3 CrossRefPubMedGoogle Scholar
  35. 35.
    Bright EE, Petrie KJ, Partridge AH, Stanton AL (2016) Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer. Breast Cancer Res Treat 158:243–251.  https://doi.org/10.1007/s10549-016-3871-3 CrossRefPubMedGoogle Scholar
  36. 36.
    Chim K, Xie SX, Stricker CT et al (2013) Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors. BMC Cancer 13:401.  https://doi.org/10.1186/1471-2407-13-401 CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Brier MJ, Chambless DL, Gross R et al (2017) Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors. Cancer 123:169–176.  https://doi.org/10.1002/cncr.30318 CrossRefPubMedGoogle Scholar
  38. 38.
    Kadakia KC, Snyder CF, Kidwell KM et al (2016) Patient-reported outcomes and early discontinuation in aromatase inhibitor-treated postmenopausal women with early stage breast cancer. Oncologist 21:539–546.  https://doi.org/10.1634/theoncologist.2015-0349 CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Kidwell KM, Harte SE, Hayes DF et al (2014) Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy. Cancer 120:2403–2411.  https://doi.org/10.1002/cncr.28756 CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Henry NL, Azzouz F, Desta Z et al (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30:936–942.  https://doi.org/10.1200/JCO.2011.38.0261 CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Liu Y, Malin JL, Diamant AL et al (2013) Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider–patient communication. Breast Cancer Res Treat 137:829–836.  https://doi.org/10.1007/s10549-012-2387-8 CrossRefPubMedGoogle Scholar
  42. 42.
    Kahn KL, Schneider EC, Malin JL et al (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45:431–439CrossRefPubMedGoogle Scholar
  43. 43.
    Quinn EM, Fleming C, O’Sullivan MJ (2016) Endocrine therapy adherence: a cross-sectional study of factors affecting adherence and discontinuation of therapy. Ir J Med Sci 185:383–392.  https://doi.org/10.1007/s11845-015-1307-4 CrossRefPubMedGoogle Scholar
  44. 44.
    Kimmick G, Edmond SN, Bosworth HB et al (2015) Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy. Breast 24:630–636.  https://doi.org/10.1016/j.breast.2015.06.010 CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Aiello Bowles EJ, Boudreau DM, Chubak J et al (2012) Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract 8:e149–e157.  https://doi.org/10.1200/JOP.2012.000543 CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Atkins L, Fallowfield L (2006) Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer Care (Engl) 42:2271–2276.  https://doi.org/10.1016/j.ejca.2006.03.004 CrossRefGoogle Scholar
  47. 47.
    Kyvernitakis I, Ziller V, Hars O et al (2014) Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer. Climacteric 17:252–259.  https://doi.org/10.3109/13697137.2013.819327 CrossRefPubMedGoogle Scholar
  48. 48.
    Bender CM, Gentry AL, Brufsky AM et al (2014) Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer. Oncol Nurs Forum 41:274–285.  https://doi.org/10.1188/14.ONF.274-285 CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Hadji P, Jackisch C, Bolten W et al (2014) COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. Ann Oncol 25:372–377.  https://doi.org/10.1093/annonc/mdt513 CrossRefPubMedGoogle Scholar
  50. 50.
    Demissie S, Silliman RA, Lash TL et al (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19:322–328.  https://doi.org/10.1200/JCO.2001.19.2.322 CrossRefPubMedGoogle Scholar
  51. 51.
    Brett J, Fenlon D, Boulton M et al (2016) Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer. Eur J Cancer Care (Engl).  https://doi.org/10.1111/ecc.12601 Google Scholar
  52. 52.
    Hershman DL, Kushi LH, Hillyer GC et al (2016) Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the breast cancer quality of care study (BQUAL). Breast Cancer Res Treat 157:133–143.  https://doi.org/10.1007/s10549-016-3788-x CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Wickersham KE, Sereika SM, Bender CM (2013) Pretreatment predictors of short-term nonadherence to oral hormonal therapy for women with breast cancer. Nurs Res 62:243–251.  https://doi.org/10.1097/NNR.0b013e318298fd70 CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Huiart L, Bouhnik A-DD, Rey D et al (2013) Complementary or alternative medicine as possible determinant of decreased persistence to aromatase inhibitor therapy among older women with non-metastatic breast cancer. PLoS ONE 8:e81677.  https://doi.org/10.1371/journal.pone.0081677 CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Grunfeld EA, Hunter MS, Sikka P, Mittal S (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59:97–102.  https://doi.org/10.1016/j.pec.2004.10.005 CrossRefPubMedGoogle Scholar
  56. 56.
    Arriola KRJ, Mason TA, Bannon KA et al (2014) Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients. Patient Educ Couns 95:98–103.  https://doi.org/10.1016/j.pec.2013.12.019 CrossRefGoogle Scholar
  57. 57.
    Heisig SR, Shedden-Mora MC, von Blanckenburg P et al (2015) Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence. Psychooncology 24:130–137.  https://doi.org/10.1002/pon.3611 CrossRefPubMedGoogle Scholar
  58. 58.
    Albert U-S, Zemlin C, Hadji P et al (2011) The impact of breast care nurses on patients’ satisfaction, understanding of the disease, and adherence to adjuvant endocrine therapy. Breast Care 6:221–226.  https://doi.org/10.1159/000329006 CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Cahir C, Dombrowski SU, Kelly CM et al (2015) Women’s experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour. Support Care Cancer 23:3115–3130.  https://doi.org/10.1007/s00520-015-2685-x CrossRefPubMedGoogle Scholar
  60. 60.
    Wells KJ, Pan TM, Vázquez-Otero C et al (2016) Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study. Support Care Cancer 24:4123–4130.  https://doi.org/10.1007/s00520-016-3229-8 CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Wickersham K, Happ MB, Bender CM (2012) “Keeping the boogie man away”: medication self-management among women receiving anastrozole therapy. Nurs Res Pract 2012:1–9.  https://doi.org/10.1155/2012/462121 CrossRefGoogle Scholar
  62. 62.
    Pellegrini I, Sarradon-Eck A, Soussan PB et al (2010) Women’s perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients’ point of view. Psychooncology 19:472–479.  https://doi.org/10.1002/pon.1593 CrossRefPubMedGoogle Scholar
  63. 63.
    Brauer ER (2016) “Winging it”: how older breast cancer survivors persist with aromatase inhibitor treatment. J Oncol Pract 12:e991–e1000.  https://doi.org/10.1200/JOP.2016.011767 CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Farias AJ, Ornelas IJ, Hohl SD et al (2017) Exploring the role of physician communication about adjuvant endocrine therapy among breast cancer patients on active treatment: a qualitative analysis. Support Care Cancer 25:75–83.  https://doi.org/10.1007/s00520-016-3389-6 CrossRefPubMedGoogle Scholar
  65. 65.
    Harrow A, Dryden R, McCowan C et al (2014) A hard pill to swallow: a qualitative study of women’s experiences of adjuvant endocrine therapy for breast cancer. BMJ Open 4:e005285.  https://doi.org/10.1136/bmjopen-2014-005285 CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Simon R, Latreille J, Matte C et al (2014) Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up. Can J Surg 57:26–32.  https://doi.org/10.1503/cjs.006211 CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Wouters H, van Geffen ECG, Baas-Thijssen MC et al (2013) Disentangling breast cancer patients’ perceptions and experiences with regard to endocrine therapy: nature and relevance for non-adherence. Breast 22:661–666.  https://doi.org/10.1016/j.breast.2013.05.005 CrossRefPubMedGoogle Scholar
  68. 68.
    Cella D, Fallowfield LJ (2008) Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 107:167–180.  https://doi.org/10.1007/s10549-007-9548-1 CrossRefPubMedGoogle Scholar
  69. 69.
    Niravath P (2013) Aromatase inhibitor-induced arthralgia: a review. Ann Oncol 24:1443–1449.  https://doi.org/10.1093/annonc/mdt037 CrossRefPubMedGoogle Scholar
  70. 70.
    Walker EM, Rodriguez AI, Kohn B et al (2010) Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol 28:634–640.  https://doi.org/10.1200/JCO.2009.23.5150 CrossRefPubMedGoogle Scholar
  71. 71.
    Hadji P, Blettner M, Harbeck N et al (2013) The patient’s anastrozole compliance to therapy (PACT) program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol.  https://doi.org/10.1093/annonc/mds653 Google Scholar
  72. 72.
    Neven P, Markopoulos C, Tanner M et al (2014) The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study. Breast 23:393–399.  https://doi.org/10.1016/j.breast.2014.02.009 CrossRefPubMedGoogle Scholar
  73. 73.
    Ziller V, Kyvernitakis I, Knöll D et al (2013) Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment-the COMPAS study. BMC Cancer 13:407.  https://doi.org/10.1186/1471-2407-13-407 CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Kirchner TR, Shiffman S (2013) Ecological momentary assessment. In: Wiley-Blackwell handbook of addiction psychopharmacology.  10.1002/9781118384404.ch20

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Leah K. Lambert
    • 1
  • Lynda G. Balneaves
    • 2
  • A. Fuchsia Howard
    • 1
  • Carolyn C. Gotay
    • 3
  1. 1.School of NursingUniversity of British ColumbiaVancouverCanada
  2. 2.College of Nursing, Rady Faculty of Health Sciences, Helen Glass Centre for NursingUniversity of ManitobaWinnipegCanada
  3. 3.School of Population and Public HealthUniversity of British ColumbiaVancouverCanada

Personalised recommendations